Accéder au contenu
Merck

1292303

USP

Glimepiride

United States Pharmacopeia (USP) Reference Standard

Synonyme(s) :

Glimepiride

Slide 1 of 1
Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

200 MG

641.00 CHF

641.00 CHF

Vérifier la disponibilité des articles du panier
Demander une commande groupée

A propos de cet article

Formule empirique (notation de Hill) :
C24H34N4O5S
Numéro CAS:
93479-97-1
Poids moléculaire :
490.62
NACRES:
NA.24
PubChem Substance ID:
329749940
UNSPSC Code:
41116107
MDL number:
MFCD00878417

Principaux documents

Voir toute la documentation

Passer à

Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider

Nom du produit

Glimepiride, United States Pharmacopeia (USP) Reference Standard

InChI key

WIGIZIANZCJQQY-RUCARUNLSA-N

SMILES string

CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)C1=O

InChI

1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)/t16-,19-

grade

pharmaceutical primary standard

API family

glimepiride

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

Gene Information

human ... ABCC8(6833), KCNJ11(3767)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Comparer avec des articles similaires

Voir la comparaison complète

Montrer les différences

1 of 4

Cet article
Y0000515BP1144Y0000516
Glimepiride United States Pharmacopeia (USP) Reference Standard

USP

1292303

Glimepiride

Glimepiride European Pharmacopoeia (EP) Reference Standard

Y0000515

Glimepiride

Glimepiride British Pharmacopoeia (BP) Reference Standard

BP1144

Glimepiride

Glimepiride for system suitability European Pharmacopoeia (EP) Reference Standard

Y0000516

Glimepiride for system suitability

manufacturer/tradename

USP

manufacturer/tradename

EDQM

manufacturer/tradename

BP

manufacturer/tradename

EDQM

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

format

neat

format

neat

format

neat

format

neat

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical
pharmaceutical small molecule

application(s)

pharmaceutical (small molecule)

API family

glimepiride

API family

glimepiride

API family

glimepiride

API family

glimepiride

Gene Information

human ... ABCC8(6833), KCNJ11(3767)

Gene Information

human ... ABCC8(6833), KCNJ11(3767)

Gene Information

human ... ABCC8(6833), KCNJ11(3767)

Gene Information

human ... ABCC8(6833), KCNJ11(3767)

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Application

Glimepiride USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
Also, for use with USP monographs such as:
  • Glimepiride Tablets
  • Pioglitazone and Glimepiride Tablets

Glimepiride is currently used to treat type 2 diabetes.

Biochem/physiol Actions

Glimepiride is a potent blocker of cardiac KATP channels activated by pinacidil with an IC50 of 6.8 nM.
Potent blocker of cardiac KATP channels.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

comparable product

Réf. du produit
Description
Tarif

related product

Réf. du produit
Description
Tarif

1292325

Glimepiride Related Compound B, United States Pharmacopeia (USP) Reference Standard

Y0000515

Glimepiride, European Pharmacopoeia (EP) Reference Standard

1292314

Glimepiride Related Compound A, United States Pharmacopeia (USP) Reference Standard

1292336

Glimepiride Related Compound C, United States Pharmacopeia (USP) Reference Standard

1292347

Glimepiride Related Compound D, United States Pharmacopeia (USP) Reference Standard

Y0001742

Glimepiride for impurity A identification, European Pharmacopoeia (EP) Reference Standard

PHR1727

Glimepiride Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1725

Glimepiride cis-Isomer (Glimepiride Related Compound A), Pharmaceutical Secondary Standard; Certified Reference Material

BP1144

Glimepiride, British Pharmacopoeia (BP) Reference Standard

PHR1726

Glimepiride Sulfonamide, pharmaceutical secondary standard, certified reference material

pictograms

Health hazard
GHS08

signalword

Warning

hcodes

H361

Hazard Classifications

Repr. 2

Classe de stockage

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

J Rosenstock et al.
Diabetes care, 19(11), 1194-1199 (1996-11-01)
To compare the efficacy and safety of two daily doses of the new sulfonylurea, glimepiride (Amaryl), each as a once-daily dose or in two divided doses, in patients with NIDDM. Of the previously treated NIDDM patients, 416 entered this multicenter
T F Veneman et al.
The Netherlands journal of medicine, 52(5), 179-186 (1998-07-04)
Disturbances in insulin secretion and insulin action are both involved in the pathophysiology of type 2 (or non-insulin-dependent) diabetes mellitus. The newly developed sulfonylurea (SU) derivative glimepiride has a marked insulin secretory effect both in vitro and in vivo, and
M Nauck et al.
Diabetes, obesity & metabolism, 15(3), 204-212 (2012-09-19)
To investigate efficacy and safety of dual therapy with liraglutide and metformin in comparison to glimepiride and metformin, and metformin monotherapy over 2 years in patients with type 2 diabetes. In the 26-week the Liraglutide Effect and Action in Diabetes
Mary T Korytkowski
Pharmacotherapy, 24(5), 606-620 (2004-05-28)
Sulfonylureas, which have evolved through two generations since their introduction nearly 50 years ago, remain the most frequently prescribed oral agents for treatment of patients with type 2 diabetes mellitus. Glyburide, glipizide, and glimepiride, the newest sulfonylureas, are as effective
H D Langtry et al.
Drugs, 55(4), 563-584 (1998-04-30)
Glimepiride is a sulphonylurea agent that stimulates insulin release from pancreatic beta-cells and may act via extrapancreatic mechanisms. It is administered once daily to patients with type 2 (non-insulin-dependent) diabetes mellitus in whom glycaemia is not controlled by diet and
Afficher tous les articles scientifiques apparentés

Questions

Reviews

No rating value

Active Filters

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique